The Future Of Plasmid DNA Upstream Optimization

The advancement of messenger RNA (mRNA) vaccines and viral vector-based gene therapies has fueled the growth opportunity for the plasmid DNA (pDNA) market. Plasmid serves as an essential starting material to unlock the power of advanced therapies, and an optimized upstream manufacturing process is crucial for producing the necessary amount of pDNA required for the growing number of therapeutic and vaccine applications available.

With demand for plasmid expected to rise over the coming years, companies developing pDNA materials need to employ the best technology possible to improve pDNA yields, increase batch success rates, and optimize cost efficiency. Developing a platform process for upstream plasmid manufacturing is an essential step which will ultimately expand the number of plasmid types you can develop, as well as the number of potential customers available to your company.

The upstream process is an important part of bringing plasmid materials to market. Plasmid DNA can be used as a drug product to directly administer the gene of interest (GOI) to patients or as an intermediate product for mRNA or viral vector production. All therapy types are rapidly expanding and will require robust manufacturing services to supply high yields of GMP-grade pDNA materials. Learn more about optimizing your pDNA upstream manufacturing processes.